CAS NO: | 142715-48-8 |
包装 | 价格(元) |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
生物活性 | CP-100356 hydrochloride is an orally active dualMDR1 (P-gp)/BCRPinhibitor, with anIC50s of 0.5 and 1.5 μM for inhibiting MDR1-mediated Calcein-AM transport and BCRP-mediated Prazosin transport, respectively. CP-100356 hydrochloride is also a weak inhibitor ofOATP1B1(IC50=~66 μM). CP-100356 hydrochloride is devoid of inhibition against MRP2 and major human P450 enzymes (IC50>15 μM)[1]. | ||||||||||||||||
IC50& Target | IC50: 0.5 μM (MDR1), 1.5 μM (BCRP) in MDCKII cells[1] | ||||||||||||||||
体外研究 (In Vitro) | CP-100356 (0.1-15 μM; pretreated for 30 min) inhibits acetoxymethyl Calcein (Calcein-AM) uptake and and Digoxin transport in human MDR1-transfected MDCKII cells, with IC50s of 0.50 μM and 1.2 μM, respectively. CP-100356 decreases the BCRP-mediated transport of Prazosin in MDCKII cells, with an IC50of 1.5 μM[1]. | ||||||||||||||||
体内研究 (In Vivo) | CP-100356 (6-24 mg/kg; p.o.) increases the systemic exposure of Fexofenadine (36- and 80-fold increase in Cmaxand AUC at the dose of 24 mg/kg) in rats[1]. | ||||||||||||||||
分子量 | 597.10 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C31H37ClN4O6 | ||||||||||||||||
CAS 号 | 142715-48-8 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) | ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 11.36 mg/mL(19.03 mM;ultrasonic and warming and heat to 60℃) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|